Citation Impact
Citing Papers
Zygomycetes in Human Disease
2000 Standout
Characterization of a canine homolog of hepatitis C virus
2011 StandoutNobel
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
Infective Endocarditis
2005 Standout
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy
2003
An overview of drug-induced acute kidney injury
2008
Steady‐state pharmacokinetics of once‐daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers*
2007
Acute kidney injury
2012 Standout
Effects of Acid‐Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir‐Boosted Atazanavir
2008
Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support
2006
Hepatitis C virus resistance to protease inhibitors
2011
Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines
2013 StandoutNobel
Correlates of acute renal failure in patients receiving parenteral amphotericin B
2001
Natural products: A continuing source of novel drug leads
2013 Standout
Current role of LC-MS in therapeutic drug monitoring
2007
Prospective Study of Amphotericin B Formulations in Immunocompromised Patients in 4 European Countries
2006
Study of Renal Safety in Amphotericin B Lipid Complex–Treated Patients
2005
Amphotericin B Nephrotoxicity in Children
2004
Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update
2014
Liposomal amphotericin B: clinical experience and perspectives
2005
Current Options in Antifungal Pharmacotherapy
2008
Clinical Pharmacokinetics and Summary of Efficacy and Tolerability of Atazanavir
2005
Optimising Antimicrobial Therapy in Diabetic Foot Infections
2007
Characterizing and Predicting Amphotericin B‐Associated Nephrotoxicity in Bone Marrow or Peripheral Blood Stem Cell Transplant Recipients
2002
Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
2003
Implant infections: adhesion, biofilm formation and immune evasion
2018 Standout
A case of disseminated histoplasmosis successfully treated with the investigational drug posaconazole
2005
Antifungal agents – clinical pharmacokinetics and drug interactions
2008
Antifungal Agents. Part I. Amphotericin B Preparations and Flucytosine
1998
Development of therapeutic antibodies for the treatment of diseases
2020 Standout
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
A Retrospective Comparison of Ceftriaxone Versus Oxacillin for Osteoarticular Infections Due to Methicillin-Susceptible Staphylococcus aureus
2011
Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring
2014 StandoutNobel
Evaluation of antiretrovirals in animal models of HIV infection
2009
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
2011 Standout
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV and Recommendations for Postexposure Prophylaxis
2005 Standout
Therapeutic drug monitoring of antiretrovirals for people with HIV
2009
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
2013 Standout
Magnesium in Man: Implications for Health and Disease
2014 Standout
Zygomycetes in Human Disease
2000 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children
2011 Standout
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study
2019 StandoutNobel
Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects
2009
Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?
2018
2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adultsa
2015 Standout
Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of Americaa
2012 Standout
2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infectionsa
2012 Standout
Markers of gut dysfunction do not explain low rifampicin bioavailability in HIV-associated TB
2017 StandoutNobel
2015 ESC Guidelines for the management of infective endocarditis
2015 Standout
Prosthetic Joint Infection
2014 Standout
Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy
2004
Guidelines for Treatment of Candidiasis
2004 Standout
Clinical Practice Guidelines for the Management of Patients with Histoplasmosis: 2007 Update by the Infectious Diseases Society of America
2007 Standout
Works of Andrew Luber being referenced
K65R-associated virologic failure in HIV-infected patients receiving tenofovir-containing triple nucleoside/nucleotide reverse transcriptase inhibitor regimens.
2004
Hypothermia Following the Intravenous Administration of Amphotericin B
1996
Therapeutic drug monitoring in HIV infection: current status and future directions
2002
Genetic Barriers to Resistance and Impact on Clinical Response
2005
Ceftriaxone Therapy for Staphylococcal Osteomyelitis: A Review
2000
Risk factors for amphotericin B- induced nephrotoxicity
1999
Enfuvirtide
2004
Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.
2005
Plasma Amprenavir Pharmacokinetics and Tolerability following Administration of 1,400 Milligrams of Fosamprenavir Once Daily in Combination with either 100 or 200 Milligrams of Ritonavir in Healthy Volunteers
2007